Stock Events

Stock Events

Zymeworks BC 

$25.40
52
+$0.09+0.36% 09:33 Today

Statistics

Day High
25.33
Day Low
25.26
52W High
29.75
52W Low
13.48
Volume
16,502
Avg. Volume
-
Mkt Cap
1.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.68
0.27
1.22
2.17
Expected EPS
2.169103
Actual EPS
N/A

Financials

-76.56%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
105.97MRevenue
-81.13MNet Income

Analyst Ratings

45.50Average Price Target
The highest estimate is 58.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZYME. It's not an investment recommendation.
NVIDIA
12
NVDA
Apple
11
AAPL
Tesla
11
TSLA
Amazon
10
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes in the biotechnology field, focusing on monoclonal antibodies, a key area of Zymeworks' research and development.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech firm that develops innovative human therapeutics, including bi-specific antibodies, directly competing with Zymeworks' platforms.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is involved in the discovery, development, and commercialization of cancer treatments, competing with Zymeworks' oncology focus.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, works on biologics for cancer, directly competing with Zymeworks in the oncology and antibody engineering space.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb Company offers a range of biopharmaceutical products, including cancer therapies that compete with Zymeworks' pipeline.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. has a broad portfolio including oncology products, competing with Zymeworks in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company focuses on oncology and biopharmaceuticals, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. is known for its work in antiviral drugs but also competes in the oncology space, overlapping with Zymeworks' interests.
Novartis
NVS
Mkt Cap286.78B
Novartis AG is a global healthcare company that competes with Zymeworks in the development of innovative cancer therapies.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca PLC is involved in the discovery and development of a wide range of pharmaceutical products, including those for cancer, making it a competitor in the oncology field.

About

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Show more...
CEO
Kenneth H. Galbraith
Employees
264
Country
United States
ISIN
US98985Y1082
WKN
000A3DSSN

Listings

STU
DE
ZA8.STU
MU
DE
ZA8.MU
XNAS
US
ZYME
F
DE
ZA8.F

0 Comments

Share your thoughts

FAQ

What is Zymeworks BC stock price today?▼
The current price of ZYME is $25.40 USD — it has increased by +0.36% in the past 24 hours. Watch Zymeworks BC stock price performance more closely on the chart.
What is Zymeworks BC stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Zymeworks BC stocks are traded under the ticker ZYME.
Is Zymeworks BC stock price growing?▼
ZYME stock has risen by +4.07% compared to the previous week, the month change is a +4.63% rise, over the last year Zymeworks BC has showed a +80.14% increase.
What is Zymeworks BC market cap?▼
Today Zymeworks BC has the market capitalization of 1.8B
When is the next Zymeworks BC earnings date?▼
Zymeworks BC is going to release the next earnings report on November 10, 2026.
What were Zymeworks BC earnings last quarter?▼
ZYME earnings for the last quarter are -0.62 USD per share, whereas the estimation was -0.56 USD resulting in a -10.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Zymeworks BC revenue for the last year?▼
Zymeworks BC revenue for the last year amounts to 105.97M USD.
What is Zymeworks BC net income for the last year?▼
ZYME net income for the last year is -81.13M USD.
How many employees does Zymeworks BC have?▼
As of August 18, 2026, the company has 264 employees.
In which sector is Zymeworks BC located?▼
Zymeworks BC operates in the Health & Wellness sector.
When did Zymeworks BC complete a stock split?▼
Zymeworks BC has not had any recent stock splits.
Where is Zymeworks BC headquartered?▼
Zymeworks BC is headquartered in MIDDLETOWN, United States.